The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
U.S. Senator Bill Cassidy (R-LA) has released a discussion draft of a sweeping, ambitious bill titled the “Americas Act”. The bill states its aim to “establish a regional trade, investment, and people-to-people partnership of countries in the Western Hemisphere”. But unlike every other U.S. trade agreement in the last century, the Americas Act actually undertakes…
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
China’s JA Solar Sets Up Shop In Arizona as Year-Old Forced Labor Law Targets Its Supply Chain Back Home
Arizona gets $60 million solar plant. But the owner is China’s JA Solar, a company that will be in the cross hairs of forced labor laws.
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended that China lose its Most-Favored Nation (MFN) tariff status. Referencing the decision to grant China permanent MFN status in 2001, Speaker McCarthy said in remarks on the House floor yesterday…
Canadian Solar is mostly Chinese-run and produced. Its solar panels in a Maine government project may be tainted by forced labor.
A Department of Energy official warns that China’s outsized role in the solar industry is a headwind for Biden’s green energy plans, and energy security.
The November trade deficit fell, but that didn’t stop the U.S. from record imports this year. The goods deficit is now over $1.1 trillion.
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.